Pfizer (PFE) Could Be 16% Undervalued On New FDA Approval In Bladder Cancer
Pfizer (PFE) is back in focus after the U.S. Food and Drug Administration approved PADCEV plus Keytruda as a platinum free neoadjuvant and adjuvant regimen for adult patients with muscle invasive bladder cancer.
See our latest analysis for Pfizer.
The latest FDA approval lands as Pfizer’s share price has been under pressure over longer periods, with a 90 day share price return that declined 8.78% but a 1 year total shareholder return of 9.43%. This suggests momentum is trying to rebuild from a weaker multi year base.
If this kind of oncology news has your attention, it could be a good moment to scan other potential opportunities in cancer and biotech using our healthcare AI stocks screener, starting with 39 healthcare AI stocks.
For Pfizer stock, the recent FDA win in bladder cancer sits against a five year record that still shows share price pressure. Are investors rethinking the business, or just nudging sentiment off the lows as valuation resets next?
Most Popular Narrative: 13.9% Undervalued
Pfizer's most followed narrative points to a fair value of $29.19 per share compared with the last close at $25.14, framing the updated FDA approvals within a broader long term thesis driven by its pipeline and business mix.
Robust expansion of Pfizer's late-stage pipeline, especially in oncology and rare diseases, with multiple high-potential launches and label expansions (e.g., Elrexfio in multiple myeloma, SV in non-small cell lung cancer, advanced ADC portfolio, and pipeline vaccines), stands to drive sustained long-term revenue and earnings growth by addressing rising global demand for innovative therapies as the population ages.
Want to see what sits behind that fair value gap for Pfizer? The narrative leans on shifting revenue mix, higher margins and a richer earnings multiple to make the numbers work.
Result: Fair Value of $29.19 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Pfizer’s narrative still faces pressure from looming patent expirations and regulatory moves on drug pricing that could limit the value investors ultimately see in the pipeline.
Find out about the key risks to this Pfizer narrative.
Next Steps
With both risks and rewards in play for Pfizer, this could be a good time to review the data yourself, weigh the trade offs, and assess the 1 key reward and 4 important warning signs.
Looking for more investment ideas beyond Pfizer?
If Pfizer’s story has you thinking more broadly about your portfolio, do not stop here. Use structured stock lists to spot opportunities before they move.
- Target potential mispricings by checking companies that screen as quality yet potentially cheap through the 49 high quality undervalued stocks.
- Prioritise stability and income by reviewing companies with stronger payout profiles via the 8 dividend fortresses.
- Dial down volatility risk by scanning companies that show resilient characteristics using the 82 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com